ACT-1004-1239
Sponsors
Idorsia Pharmaceuticals Ltd.
Conditions
Healthy
Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects
CompletedNCT03869320
Start: 2019-03-25End: 2019-07-11Updated: 2020-01-10
Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239
CompletedNCT04286750
Start: 2020-07-11End: 2020-09-25Updated: 2021-01-20